Norris Medicines Limited has scheduled a meeting of its Board of Directors to be held on Saturday, 30th May, 2026, at the Registered Office of the Company situated at Plot No. 801/P, GIDC, Ankleshwar, Gujarat, 393002.
The Board will consider and approve the following business items:
- Audited Financial Results for the quarter and year ended 31st March, 2026
- Audit Report
- Cash Flow Statement
- Statement of Asset and Liability
- Declaration for un-modified opinion
- Any other business with permission of Chair and with the consent of a majority of the Directors present in the Meeting including at least one Independent Director
The company has confirmed that the Trading Window for dealing in securities of the Company is already closed from April 01, 2026, in accordance with the Company's Code of Conduct for Prevention of Insider Trading and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed until Forty-Eight (48) hours after the declaration of Audited financial results for the quarter ended March 31, 2026 on the Stock Exchange.
The intimation is addressed to the Department of Corporate Service (DCS-CRD) of BSE Limited and is signed by Vimal Shah, Director (DIN: 01506655).